Anne Shiflett

Catalent Maryland, Inc. engages in the manufactures of biopharmaceuticals products such as viral vectors, vaccines, and proteins and oncolytic viruses. It offers process development, GMP manufacturing, fill and finish, analytical development, master and working cell and virus banks, quality systems, and stabilities studies services. The company was founded by Marco A. Chacon in 1990 and is headquartered in Baltimore, MD.

Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO.

Part of Anywhere Real Estate, Inc., O'Connor, Piper, & Flynn, ERA is a company that provides real estate services. The company is based in Timonium, MD.

AgentSmith, Inc. develops revenue optimization and management solutions for the broadcast media industry. The company was founded by Michael Cooper and David Lalich in 2001 and is headquartered in Baltimore, MD.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies